International Assets Investment Management LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

by · The Cerbat Gem

International Assets Investment Management LLC raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 86,013.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 880,939 shares of the biopharmaceutical company’s stock after purchasing an additional 879,916 shares during the quarter. International Assets Investment Management LLC owned 0.80% of Regeneron Pharmaceuticals worth $926,078,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at $26,000. Sachetta LLC raised its position in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter valued at $28,000. Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at $33,000. Finally, Family Firm Inc. purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.2 %

Shares of NASDAQ REGN opened at $941.39 on Thursday. The company has a market capitalization of $103.73 billion, a price-to-earnings ratio of 27.81, a price-to-earnings-growth ratio of 3.40 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The business has a 50-day moving average of $1,098.29 and a two-hundred day moving average of $1,040.67. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period in the previous year, the business earned $8.79 EPS. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on REGN shares. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. lifted their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,102.19.

Read Our Latest Stock Report on Regeneron Pharmaceuticals

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).